Arch Biopartners Inc. (TSXV: ARCH)
ARCH trades on the TSX Venture Exchange in Life Sciences, headquartered in Ontario. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of October 31, 2026. US$ figures convert C$ at 1.4257 C$ per US$, the Bank of Canada daily rate for November 13, 2026. Close and returns: Yahoo Finance daily closes for ARCH.V, last bar 2026-11-13, computed by MarginsX.
Profile
| Field | Value |
|---|---|
| Ticker | ARCH on the TSX Venture Exchange |
| Yahoo symbol | ARCH.V |
| Sector | Life Sciences |
| Headquarters | Ontario |
| Listed | 2015-02-23 |
| Listing type | Other |
| Shares outstanding | 67,933,289 |
| Also listed on | No interlisting on the TMX list |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | No SEC filer matched on exact name with a Canadian address or US interlisting |
| Website | No company website on record |
Returns
| Window | Return |
|---|---|
| 1 day | -8.8% |
| 1 week | +6.9% |
| 1 month | +8.1% |
| 3 months | -19.1% |
| 6 months | +116.3% |
| Year to date | -23.8% |
| 1 year | -8.8% |
| From 52-week high | -35.9% |
| 52-week range | C$0.4100 to C$1.45 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
147 documents in 5 types. Each title links to the document at its source.
Annual financial statements (14)
| Document | Type | Filed |
|---|---|---|
| 2013 Q4 Year-end Financial Statements Period Q4 2014 | Annual financial statements | 2014-01-28 |
| 2012 Q4 Year-end Financial Statements Period Q4 2013 | Annual financial statements | 2013-01-29 |
| 2011 Q4 Year-end Financial Statements Period Q4 2011 | Annual financial statements | No date |
| 2022 Q4 Year-end Financial Statements Period Q4 2022 | Annual financial statements | No date |
Interim financial statements (51)
| Document | Type | Filed |
|---|---|---|
| 2025 Q4 Interim Financial Statements Period Q4 2025 | Interim financial statements | 2026-10-27 |
| 2025 Q2 Interim Financial Statements Period Q2 2025 | Interim financial statements | 2026-10-27 |
| 2025 Q3 Interim Financial Statements Period Q3 2025 | Interim financial statements | 2026-10-27 |
| 2026 Q2 Interim Financial Statements Period Q2 2026 | Interim financial statements | 2026-10-27 |
MD&A (63)
| Document | Type | Filed |
|---|---|---|
| 2023 Q4 Management Discussion and Analysis Period Q4 2023 | MD&A (annual) | No date |
| 2013 Q4 Management Discussion and Analysis Period Q4 2013 | MD&A (annual) | No date |
| 2018 Q4 Management Discussion and Analysis Period Q4 2018 | MD&A (annual) | No date |
| 2022 Q4 Management Discussion and Analysis Period Q4 2022 | MD&A (annual) | No date |
Material change report (17)
| Document | Type | Filed |
|---|---|---|
| 2025-11-30 ARCH Material Change Report | Material change report | 2025-11-30 |
| 2024-08-07 ARCH Material Change Report | Material change report | 2024-08-07 |
| 2020-12-22 ARCH Material Change Report | Material change report | 2020-12-22 |
| 2020-07-06 ARCH Material Change Report | Material change report | 2020-07-06 |
Other (2)
| Document | Type | Filed |
|---|---|---|
| s and corporate strategy in the latest corporate presentation (PDF) . Investor Information Find | Investor presentation | No date |
| Corporate Presentation November 2026 Learn more about Arch Biopartners’ clinical progress and corporate strategy in the latest | Investor presentation | No date |
Sources: Company investor-relations website (links only, documents not copied). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
No CIRO halt notices for this company in our data.
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2015-01-22 | Equity, Option To Acquire, Security To Be Acquired | US$265K | US$265K | SEC EDGAR |
| 2014-08-18 | Equity, Option To Acquire, Security To Be Acquired | US$156K | US$156K | SEC EDGAR |
| 2014-04-04 | Equity, Option To Acquire, Security To Be Acquired | US$140K | US$140K | SEC EDGAR |
| 2014-03-06 | Equity, Option To Acquire, Security To Be Acquired | US$70K | US$70K | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on exact issuer name. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| OTC | Ocumetics Technology Corp. | TSXV | C$56.2M | -9.8% | -63.7% |
| WOLF | Grey Wolf Health Corp. | TSXV | C$57.2M | -5.2% | +24.1% |
| AIAI | NetraMark Holdings Inc. | TSX | C$54.7M | -4.8% | -52.0% |
| TELY | TelyRx Holdings Inc. | TSX | C$64.3M | -25.7% | Under a year of closes |
| EK | Everkind Wellness Inc. | TSXV | C$65.0M | -27.8% | Under a year of closes |
The app has the price chart, every filing, private raises and the full peer set for ARCH.
Open in the app